Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05134727 · ClinicalTrials.gov registry record · Phase 1
Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT05134727 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 63 participants.
The verdict
NCT05134727, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a phase I, First-in-Human study in healthy participants, performed at a single study center, consisting of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.
Interventions
- DRUG Placebo
- DRUG AZD5055
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05134727
The ClinicalTrials.gov registry entry for NCT05134727 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05134727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05134727 about?
NCT05134727 is a clinical study titled "Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants". This is a phase I, First-in-Human study in healthy participants, performed at a single study center, consisting of 2 parts: Part 1 is a single ascending dose (SAD) study and Part 2 is a multiple ascending dose (MAD) study.
What is the current status of trial NCT05134727?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2021-11-18. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT05134727?
The interventions under investigation include: Placebo (DRUG), AZD5055 (DRUG).
Who is sponsoring clinical trial NCT05134727?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.